Recommendation of the President – Tepkinly (epcoritamab)
On 29 August 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 119/2025 on the appraisal of drug Tepkinly (epcoritamab) as part of the drug program “Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)”